REGN Regeneron Pharmaceuticals, Inc. - Common Stock
Regeneron Pharmaceuticals, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
और पढ़ें
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Company history
The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos in 1988.
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
On March 26, 2012, Bloomberg announced that Sanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than its competitors. The new drug would target the PCSK9 gene.
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof-of-concept data, and $650 million from the development of REGN2810. REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best publicly listed company of the 2010s, with a total return of 1,457%. Regeneron Pharmaceuticals was home to the two highest-paid pharmaceutical executives as of 2020.
In October 2017, Regeneron made a deal with the Biomedical Advanced Research and Development Authority (BARDA) that the U.S. government would fund 80% of the costs for Regeneron to develop and manufacture antibody-based medications, which subsequently, in 2020, included their COVID-19 treatments, and Regeneron would retain the right to set prices and control production. This deal was criticized in The New York Times. Such deals are not unusual for routine drug development in the American pharmaceutical market.
In 2019, the company was added to the Dow Jones Sustainability World Index.
In May 2020, Regeneron announced it would repurchase approx. 19.2 million of its shares for around $5 billion, held directly by Sanofi. Prior to the transaction, Sanofi held 23.2 million Regeneron shares.
In August 2023, Regeneron announced it would acquire Decibel Therapeutics.
In May 2025, the company was awarded $135.6 million in compensatory damages and $271.2 million in punitive damages in the United States District Court for the District of Delaware in a victorious antitrust case filed against Amgen. Regeneron alleged Amgen employed anticompetitive practices to exclude Praluent from the market and elevate Amgen's rival Repatha.
Experimental treatment for COVID-19
On February 4, 2020, the U.S. Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19.
In July 2020, under Operation Warp Speed, Regeneron was awarded a $450 million government contract to manufacture and supply its experimental treatment REGN-COV2, an artificial "antibody cocktail" which was then undergoing clinical trials for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection. The $450 million came from the Biomedical Advanced Research and Development Authority (BARDA), the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and Army Contracting Command. Regeneron expected to produce 70,000–300,000 treatment doses or 420,000–1,300,000 prevention doses. "By funding this manufacturing effort, the federal government will own the doses expected to result from the demonstration project," the government said in its July 7 news release. Regeneron similarly said in its own news release that same day that "the government has committed to making doses from these lots available to the American people at no cost and would be responsible for their distribution," noting that this depended on the government granting emergency use authorization or product approval. California based laboratory, FOMAT, is part of the clinical investigation through their doctors Augusto and Nicholas Focil.
In October 2020 when U.S. President Donald Trump was infected with COVID-19 and taken to Walter Reed National Military Medical Center in Bethesda, Maryland, he was administered REGN-COV2. His doctors obtained it from Regeneron via a compassionate use request (as clinical trials had not yet been completed and the drug had not yet been approved by the US Food and Drug Administration (FDA)). On October 7, Trump posted a five-minute video to Twitter reasserting that this drug should be "free." That same day, Regeneron filed with the FDA for emergency use authorization. In the filing, it specified that it currently had 50,000 doses and that it expected to reach a total of 300,000 doses "within the next few months." The FDA granted approval for emergency use authorization in November 2020.
Marketed products
Arcalyst (rilonacept) is used for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.
Eylea (aflibercept injection) was approved by the U.S. Food and Drug Administration (FDA) in November 2011 to treat a common cause of blindness in the elderly. Eylea is reported to cost $11,000 per year for each eye treated.
Zaltrap (aflibercept injection) is used for metastatic colorectal cancer approved by the FDA in August 2012.
Praluent (alirocumab) is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by the FDA in July 2015, It is reported to cost $4,500 to $8,000 per year.
Dupixent (dupilumab injection) is for the treatment of adolescent and adult patients' atopic dermatitis. It was approved by the FDA in March 2017 and is reported to cost $37,000 per year.
Kevzara (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment of adults with rheumatoid arthritis approved by the FDA in May 2017. Trials commenced in March 2020 to evaluate the effectiveness of Kevzara in the treatment of COVID-19.
Libtayo (cemiplimab injection) is a monoclonal antibody targeting the PD-1 pathway as a checkpoint inhibitor, for the treatment of people with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Libtayo was approved by the FDA in September 2018.
Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of three antibodies, developed to treat deadly Ebola virus. In October 2020, the U.S. Food and Drug Administration (FDA) approved it with an indication for the treatment of infection caused by Zaire ebolavirus.
Veopoz (pozelimab-bbfg) is a fully human monoclonal antibody targeting complement factor C5, a protein involved in complement system activation. In August 2023, it was approved by the FDA for children and adults with CHAPLE disease or CD55-deficient protein-losing enteropathy.
Technology platforms
Trap Fusion Proteins: Regeneron's Trap technology creates high-affinity product candidates for signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two fully human receptor components and a fully human immunoglobulin-G constant region.
Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.
The Regeneron Genetics Center is a distinct subsidiary of Regeneron, focused on sequencing human exomes. To date, the Regeneron Genetics Center has sequenced over 3,000,000 exomes.
Financial performance
Key people
The founders Leonard Schleifer and George Yancopoulos are reported to hold $1.3 billion and $900 million in company stock, respectively. Both are from Queens, New York. Schleifer was formerly a professor of medicine at Weill Cornell Medical School. Yancopoulos was a post-doctoral fellow, and MD/PhD student at Columbia University. Yancopoulos was involved in each drug's development.
In 2026, the Wall Street Journal noted that George Yancopoulos has 1000 patents, and is building Regeneron through internal science and discovery, not acquisitions. .
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
REGN स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
REGN स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
लाभांश यील्ड, भुगतान अनुपात, लाभांश इतिहास, 5Y CAGR
| एक्स-डेट | राशि |
|---|---|
| 18 अगस्त 2026 | $0.9400 |
| 20 मई 2026 | $0.9400 |
| 20 फ़रवरी 2026 | $0.9400 |
| 20 नवमबर 2025 | $0.8800 |
| 18 अगस्त 2025 | $0.8800 |
| 20 मई 2025 | $0.8800 |
| 20 फ़रवरी 2025 | $0.8800 |
REGN विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 8 21.6%
- खरीदें 18 48.6%
- होल्ड 11 29.7%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
27 विश्लेषक · 2026-08-19Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $14.29 | $10.47 | 3.8% |
| 31 मार्च 2026 | $9.47 | $9.12 | 0.35% |
| 31 दिसमबर 2025 | $11.44 | $10.83 | 0.61% |
| 30 सितमबर 2025 | $11.83 | $9.78 | 2.0% |
| 30 जून 2025 | $12.89 | $8.61 | 4.3% |
| 31 मार्च 2025 | $8.22 | $9.00 | -0.78% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| ABBV | — | 96.8 | 8.6% | 6.9% | 15367.3% | — |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | — |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 16
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Cost of Revenue | · | · | · | · | · | · | $403M | $238M | $203M | $195M | $242M | $129M | |
| R&D Expense | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B | $1.62B | $1.27B | |
| SG&A Expense | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B | $839M | $519M | |
| Operating Expenses | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B | $3.79B | $3.53B | $2.85B | $2.00B | |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B | $1.25B | $824M | |
| Interest Expense | · | · | $73M | $59M | $57M | $57M | $30M | $28M | $25M | $7M | $14M | $37M | |
| Other Non-op | $1.70B | $844M | $225M | $179M | $436M | $291M | $250M | $47M | $24M | $6M | $-13M | $-25M | |
| Pretax Income | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B | $1.23B | $761M | |
| Income Tax | $726M | $367M | $246M | $520M | $1.25B | $297M | $313M | $109M | $880M | $434M | $589M | $423M | |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 | $6.17 | $3.36 | |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | |
| Shares (Basic) | 104,600,000 | 107,900,000 | 106,700,000 | 107,100,000 | 105,700,000 | 107,600,000 | 109,200,000 | 107,900,000 | 106,300,000 | 104,700,000 | 103,061,000 | 100,612,000 | |
| Shares (Diluted) | 108,600,000 | 115,100,000 | 113,700,000 | 113,500,000 | 112,200,000 | 115,100,000 | 114,600,000 | 114,800,000 | 115,900,000 | 116,300,000 | 115,230,000 | 113,413,000 | |
| EBITDA | $4.12B | $4.47B | $4.47B | $5.08B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B | $1.33B | $891M |
बैलेंस शीट 27
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B | $813M | $535M | $809M | $649M | |
| Short-term Investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B | $1.60B | $1.34B | $597M | $503M | $236M | $252M | |
| Receivables | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $4.11B | $2.10B | $1.72B | $1.54B | $1.34B | $1.15B | $739M | |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B | $1.42B | $1.15B | $726M | $399M | $239M | $129M | |
| Prepaid Expense | $475M | $349M | $387M | $411M | $332M | $161M | $274M | $243M | $225M | $131M | $164M | $79M | |
| Current Assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B | $4.33B | $3.18B | $2.92B | $2.08B | |
| PP&E (Net) | · | · | · | · | $3.48B | $3.22B | $2.89B | $2.58B | $2.36B | $2.08B | $1.59B | $974M | |
| PP&E (Gross) | · | · | · | · | · | · | $3.81B | $3.30B | $2.92B | $2.51B | $1.93B | $1.23B | |
| Accum. Depreciation | · | · | · | · | · | · | $922M | $729M | $566M | $426M | $331M | $254M | |
| Intangibles | $1.26B | $1.15B | $1.04B | $916M | $7M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $1.82B | $1.14B | $444M | $336M | $216M | $168M | $145M | $127M | $78M | $20M | $6M | $3M | |
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Accounts Payable | $939M | $790M | $607M | $589M | $564M | $476M | $418M | $218M | $178M | $879M | $644M | $483M | |
| Short-term Debt | · | · | · | · | · | · | $0 | · | · | · | · | · | |
| Current Liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B | $2.10B | $1.44B | $1.14B | $1.24B | $811M | $655M | |
| Capital Leases | $229M | $204M | $69M | $56M | · | · | · | $708M | · | · | · | · | |
| Other Non-current Liabilities | $2.02B | $1.57B | $854M | $638M | $680M | $687M | $318M | $362M | $152M | $100M | $116M | $40M | |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B | $1.95B | $1.29B | |
| Total Debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | · | · | · | · | · | · | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $108.0K | $106.0K | $102.0K | |
| Paid-in Capital | $13.99B | $12.86B | $11.35B | $9.95B | $8.09B | $6.72B | $4.43B | $3.91B | $3.51B | $3.03B | $3.10B | $2.45B | |
| Retained Earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B | $7.38B | $5.25B | $2.95B | $1.75B | $853M | $217M | |
| Treasury Stock | $18.61B | $15.17B | $12.56B | $10.35B | $8.26B | $6.61B | $740M | $396M | $316M | $316M | $306M | $170M | |
| AOCI | $78M | $-8M | $-81M | $-239M | $-26M | $29M | $21M | $-12M | $600.0K | $-13M | $9M | $52M | |
| Stockholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B | $3.65B | $2.55B | |
| Liabilities + Equity | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Shares Outstanding | 137,600,000 | 136,000,000 | 133,100,000 | 130,400,000 | 126,200,000 | 121,500,000 | 113,300,000 | · | · | · | · | · |
नकदी प्रवाह 19
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $544M | $483M | $421M | $341M | $286M | $236M | $210M | $148M | $146M | $105M | $75M | $53M | |
| Stock-based Comp | $994M | $983M | $885M | $725M | $602M | $432M | $464M | $427M | $507M | $560M | $459M | $322M | |
| Deferred Tax | $-785M | $-757M | $-838M | $-746M | $-147M | $76M | $-131M | $-140M | $319M | $-360M | $-130M | $-46M | |
| Amort. of Intangibles | $179M | $129M | $92M | $38M | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-278M | $-700M | $172M | $356M | $-1.73B | $-1.64B | $-230M | $-685M | $-863M | $273M | $291M | $86M | |
| Operating Cash Flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B | $1.33B | $752M | |
| CapEx | $898M | $756M | $719M | $590M | $552M | $615M | $430M | $383M | $273M | $512M | $678M | $333M | |
| Investing Cash Flow | $-629M | $-2.47B | $-3.19B | $-3.78B | $-5.38B | $-71M | $-2.03B | $-1.46B | $-1.01B | $-1.05B | $-908M | $-421M | |
| Debt Issued | · | · | · | $0 | $0 | $1.98B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | · | · | · | $0 | $0 | $1.98B | · | · | · | · | · | · | |
| Stock Issued | $636M | $1.47B | $1.15B | $1.52B | $1.67B | $2.58B | $212M | $114M | $240M | $127M | $206M | $126M | |
| Stock Repurchased | $3.44B | $2.60B | $2.23B | $2.08B | $1.65B | $5.85B | $276M | $4M | $0 | $0 | · | · | |
| Net Stock Activity | $-2.80B | $-1.14B | $-1.09B | $-563M | $27M | $-3.27B | $-64M | $110M | $240M | $127M | $206M | $126M | |
| Dividends Paid | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-3.72B | $-2.20B | $-1.79B | $-1.01B | $-1.01B | $-1.97B | $-252M | $-77M | $-24M | $-700M | $-263M | $-219M | |
| Net Change in Cash | $635M | $-249M | $-382M | $221M | $691M | $577M | $150M | $655M | $278M | $-261M | $160M | $113M | |
| Taxes Paid | $1.25B | $743M | $870M | $1.50B | $1.22B | $188M | $342M | $206M | $755M | $481M | $276M | $60M | |
| Free Cash Flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B | $2.00B | $2.00B | $1.81B | $1.03B | $961M | $653M | $410M | |
| Levered FCF | · | · | $3.81B | $4.37B | $6.48B | $1.95B | $1.97B | $1.79B | · | · | $645M | $393M |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | |
| Net Margin | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | |
| Pretax Margin | 36.5% | 33.7% | 32.0% | 39.9% | 58.0% | 44.8% | 30.9% | 38.0% | 35.4% | 27.4% | 29.8% | 27.5% | |
| EBITDA Margin | 28.7% | 31.5% | 34.1% | 41.7% | 57.5% | 44.9% | 30.8% | 40.0% | 37.9% | 29.5% | 32.3% | 31.6% | |
| ROA | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% | 13.5% | 10.2% | |
| ROE | 14.7% | 15.0% | 15.5% | 19.7% | 44.8% | 33.2% | 19.6% | 29.4% | 22.6% | 22.1% | 20.5% | 15.4% | |
| ROIC | 9.3% | 11.8% | 13.6% | 17.2% | 37.3% | 25.4% | 17.4% | 27.7% | 19.5% | 20.1% | 17.8% | 14.8% |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 | 3.6 | 3.7 | 4.5 | 3.8 | 2.6 | 3.6 | 3.3 | |
| Quick Ratio | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 | 2.5 | 2.5 | 3.1 | 2.6 | 1.9 | 2.7 | 2.5 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | 55.4 | 79.8 | 156.1 | 62.9 | 73.2 | 89.9 | · | · | 87.9 | 22.4 |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.5 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 0.8 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 0.4 | 0.6 | 1.3 | 1.3 | |
| Receivables Turnover | 2.4 | 2.4 | 2.4 | 2.1 | 3.2 | 3.3 | 4.1 | 4.1 | 4.1 | 3.9 | 4.3 | 3.7 |
विकास दरें 9
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.99% | 8.3% | 7.8% | -24.3% | 89.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.6% | -4.0% | 15.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 8.2% | 10.3% | -9.0% | -46.9% | 135.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 2.8% | -18.9% | 4.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 2.1% | 11.6% | -8.9% | -46.3% | 129.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.3% | -18.2% | 4.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 5.1% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Net Income TTM | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| Market Cap | $106.21B | $96.88B | $116.90B | $94.08B | · | · | · | · | · | · | · | · | |
| Enterprise Value | $99.59B | $89.85B | $108.04B | $88.32B | · | · | · | · | · | · | · | · | |
| P/E | 18.6 | 18.6 | 25.3 | 18.9 | 8.8 | 15.8 | 20.3 | 17.5 | 36.4 | 47.7 | 98.3 | 137.7 | |
| P/S | 7.4 | 6.8 | 8.9 | 7.7 | · | · | · | · | · | · | · | · | |
| P/B | 3.4 | 3.3 | 4.5 | 4.2 | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.5 | 3.4 | 4.7 | 4.3 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 21.3 | 21.9 | 25.4 | 18.8 | · | · | · | · | · | · | · | · | |
| P / FCF | 26.0 | 26.4 | 30.2 | 21.3 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | 24.2 | 20.1 | 24.2 | 17.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | 24.4 | 24.5 | 27.9 | 20.0 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.9 | 6.3 | 8.2 | 7.3 | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.35% | 0.00% | 0.00% | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% | 1.0% | 0.73% | |
| Payout Ratio | 8.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Annual Payout | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · |
आय विवरण 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B | $3.43B | $3.36B | $3.16B | $3.16B | $3.41B | $2.94B | |
| R&D Expense | $1.63B | $1.54B | $1.63B | $1.48B | $1.42B | $1.33B | $1.41B | $1.27B | $1.20B | $1.25B | $1.18B | $1.08B | $1.09B | $1.10B | $1.04B | $911M | |
| SG&A Expense | $662M | $648M | $775M | $658M | $634M | $633M | $792M | $714M | $759M | $689M | $738M | $640M | $652M | $601M | $660M | $529M | |
| Operating Expenses | $3.00B | $2.96B | $3.00B | $2.73B | $2.60B | $2.44B | $2.80B | $2.54B | $2.48B | $2.39B | $2.46B | $2.25B | $2.14B | $2.22B | $2.27B | $1.71B | |
| Operating Income | $1.29B | $643M | $880M | $1.03B | $1.08B | $592M | $990M | $1.18B | $1.07B | $751M | $973M | $1.11B | $1.02B | $947M | $1.15B | $1.22B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $16M | · | $18M | $19M | $18M | · | $15M | |
| Other Non-op | $245M | $201M | $176M | $756M | $443M | $322M | $-22M | $327M | $573M | $-35M | $193M | $18M | $85M | $-71M | $195M | $301M | |
| Pretax Income | $1.53B | $831M | $1.04B | $1.76B | $1.52B | $905M | $958M | $1.49B | $1.63B | $701M | $1.15B | $1.11B | $1.08B | $858M | $1.32B | $1.51B | |
| Income Tax | $231M | $104M | $199M | $303M | $127M | $96M | $40M | $152M | $196M | $-21M | $-12M | $103M | $114M | $40M | $128M | $194M | |
| Net Income | $1.30B | $727M | $845M | $1.46B | $1.39B | $809M | $918M | $1.34B | $1.43B | $722M | $1.16B | $1.01B | $968M | $818M | $1.20B | $1.32B | |
| EPS (Basic) | $12.62 | $6.99 | $8.16 | $14.09 | $13.24 | $7.58 | $8.55 | $12.40 | $13.25 | $6.70 | $10.88 | $9.48 | $9.05 | $7.64 | $11.18 | $12.31 | |
| EPS (Diluted) | $12.23 | $6.75 | $7.78 | $13.62 | $12.81 | $7.27 | $8.12 | $11.54 | $12.41 | $6.27 | $10.21 | $8.89 | $8.50 | $7.17 | $10.48 | $11.66 | |
| Shares (Basic) | 102,800,000 | 104,000,000 | -210,800,000 | 103,600,000 | 105,100,000 | 106,700,000 | -216,100,000 | 108,100,000 | 108,100,000 | 107,800,000 | -213,700,000 | 106,300,000 | 107,000,000 | 107,100,000 | -214,500,000 | 106,900,000 | |
| Shares (Diluted) | 106,000,000 | 107,700,000 | -218,400,000 | 107,200,000 | 108,600,000 | 111,200,000 | -231,600,000 | 116,200,000 | 115,400,000 | 115,100,000 | -227,600,000 | 113,400,000 | 113,900,000 | 114,000,000 | -226,400,000 | 112,800,000 | |
| EBITDA | $1.29B | $766M | · | $1.03B | $1.08B | $719M | · | $1.18B | $1.07B | $866M | · | $1.11B | $1.02B | $1.05B | · | $1.22B |
बैलेंस शीट 24
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B | $2.01B | $1.92B | $2.60B | $2.73B | $2.15B | $1.94B | $3.92B | $3.11B | $3.49B | |
| Short-term Investments | $5.54B | $5.79B | $5.49B | $5.94B | $5.47B | $5.26B | $6.52B | $7.78B | $7.89B | $7.92B | · | $7.76B | $6.99B | $5.04B | · | $3.53B | |
| Receivables | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | $5.56B | $6.21B | $6.11B | $5.72B | $5.22B | · | $5.58B | $5.12B | $5.12B | · | $5.55B | |
| Inventory | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | $3.19B | $3.09B | $3.02B | $2.87B | $2.71B | · | $2.56B | $2.51B | $2.42B | · | $2.41B | |
| Prepaid Expense | $802M | $621M | $475M | $596M | $574M | $469M | $349M | $412M | $682M | $415M | · | $575M | $366M | $406M | · | $446M | |
| Current Assets | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | $17.57B | $18.66B | $19.33B | $19.08B | $18.87B | · | $18.63B | $16.92B | $16.91B | · | $15.43B | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $3.70B | |
| Intangibles | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | $1.17B | $1.15B | $1.12B | $1.10B | $1.06B | · | $1.02B | $953M | $929M | · | $804M | |
| Other Non-current Assets | $2.31B | $2.13B | $1.82B | $1.67B | $1.54B | $1.39B | $1.14B | $1.04B | $994M | $470M | · | $410M | $393M | $350M | · | $320M | |
| Total Assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Accounts Payable | $1.16B | $1.03B | $939M | $904M | $724M | $706M | $790M | $497M | $562M | $671M | · | $537M | $547M | $600M | · | · | |
| Current Liabilities | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | $3.57B | $3.94B | $3.66B | $3.51B | $3.58B | · | $3.60B | $3.10B | $3.10B | · | $2.88B | |
| Capital Leases | · | · | $229M | · | · | · | $204M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.28B | $2.13B | $2.02B | $1.86B | $1.70B | $1.67B | $1.57B | $1.54B | $1.46B | $908M | · | $832M | $717M | $677M | · | $599M | |
| Total Liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B | $8.12B | $7.88B | $7.38B | · | $7.26B | $6.64B | $6.56B | · | $6.24B | |
| Total Debt | $1.99B | $1.99B | · | $1.99B | $1.99B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $14.70B | $14.40B | $13.99B | $13.79B | $13.49B | $13.19B | $12.86B | $12.70B | $12.32B | $11.94B | · | $11.25B | $10.89B | $10.60B | · | $9.52B | |
| Retained Earnings | $37.62B | $36.42B | $35.80B | $35.05B | $33.68B | $32.38B | $31.67B | $30.76B | $29.41B | $27.98B | · | $26.10B | $25.09B | $24.12B | · | $22.11B | |
| Treasury Stock | $20.57B | $19.41B | $18.61B | $17.94B | $17.28B | $16.22B | $15.17B | $14.19B | $13.46B | $12.86B | · | $12.27B | $11.77B | $11.05B | · | $9.91B | |
| AOCI | $-36M | $12M | $78M | $69M | $52M | $29M | $-8M | $60M | $-70M | $-77M | · | $-177M | $-198M | $-182M | · | $-275M | |
| Stockholders' Equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B | $29.33B | $28.21B | $26.99B | $25.97B | $24.90B | $24.02B | $23.50B | $22.66B | $21.44B | |
| Liabilities + Equity | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Shares Outstanding | 138,000,000 | 137,900,000 | 137,600,000 | 136,200,000 | 136,200,000 | 136,100,000 | 136,000,000 | 135,300,000 | 134,800,000 | 134,200,000 | 133,100,000 | 132,100,000 | 131,600,000 | 131,400,000 | 130,400,000 | 129,000,000 |
नकदी प्रवाह 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $124M | $123M | $145M | $137M | $135M | $127M | $126M | $122M | $121M | $114M | $113M | $105M | $103M | $100M | $100M | $93M | |
| Stock-based Comp | $243M | $257M | $249M | $237M | $252M | $256M | $304M | $225M | $223M | $230M | $240M | $204M | $202M | $239M | $232M | $166M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $21M | $16M | |
| Other Non-cash | · | $-29M | · | · | · | $-146M | · | · | · | $446M | · | · | · | $212M | · | · | |
| Operating Cash Flow | $813M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B | $1.29B | $354M | $1.51B | $1.09B | $1.11B | $1.02B | $1.37B | $1.72B | $629M | |
| CapEx | $240M | $231M | $249M | $201M | $219M | $229M | $200M | $242M | $180M | $134M | $251M | $176M | $113M | $178M | $152M | $142M | |
| Investing Cash Flow | $-93M | $-429M | $220M | $-403M | $-1.09B | $648M | $351M | $-574M | $-557M | $-1.69B | $-66M | $-496M | $-2.39B | $-236M | $-1.86B | $192M | |
| Stock Issued | $49M | $163M | $504M | $40M | $32M | $61M | $91M | $255M | $438M | $682M | $301M | $269M | $91M | $485M | $373M | $318M | |
| Stock Repurchased | $1.17B | $794M | $672M | $664M | $1.06B | $1.04B | $973M | $735M | $604M | $291M | $289M | $546M | $689M | $711M | $431M | $935M | |
| Net Stock Activity | · | $-631M | · | · | · | $-981M | · | · | · | $391M | · | · | · | $-226M | · | · | |
| Dividends Paid | $97M | $98M | $93M | $91M | $93M | $94M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.22B | $-802M | $-780M | $-718M | $-1.13B | $-1.09B | $-1.14B | $-634M | $-478M | $47M | $-446M | $-407M | $-614M | $-322M | $-248M | $-725M | |
| Net Change in Cash | $-505M | $-153M | $611M | $498M | $-1.08B | $604M | $477M | $84M | $-682M | $-128M | $578M | $210M | $-1.98B | $809M | $-385M | $96M | |
| Free Cash Flow | · | $848M | · | · | · | $816M | · | · | · | $1.38B | · | · | · | $1.19B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $1.36B | · | · | · | $1.17B | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 30.1% | 17.8% | · | 27.4% | 29.4% | 19.5% | · | 31.7% | 30.1% | 23.9% | · | 33.0% | 32.2% | 29.9% | · | 41.7% | |
| Net Margin | 30.2% | 20.2% | · | 38.9% | 37.9% | 26.7% | · | 36.0% | 40.4% | 23.0% | · | 30.0% | 30.7% | 25.9% | · | 44.8% | |
| Pretax Margin | 35.6% | 23.1% | · | 47.0% | 41.3% | 29.9% | · | 40.1% | 45.9% | 22.3% | · | 33.0% | 34.3% | 27.1% | · | 51.4% | |
| EBITDA Margin | 30.1% | 21.2% | · | 27.4% | 29.4% | 23.7% | · | 31.7% | 30.1% | 27.5% | · | 33.0% | 32.2% | 33.1% | · | 41.7% | |
| ROA | 3.2% | 1.8% | · | 3.8% | 3.8% | 2.2% | · | 3.9% | 4.3% | 2.2% | · | 3.4% | 3.4% | 2.9% | · | 5.1% | |
| ROE | 4.2% | 2.4% | · | 4.8% | 4.8% | 2.9% | · | 4.9% | 5.5% | 2.9% | · | 4.3% | 4.3% | 3.8% | · | 6.8% | |
| ROIC | 3.3% | 1.7% | · | 2.6% | 3.1% | 1.7% | · | 3.4% | 3.1% | 2.7% | · | 3.8% | 3.5% | 3.5% | · | 4.5% |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.6 | · | 4.1 | 4.6 | 4.9 | · | 5.3 | 5.4 | 5.3 | · | 5.2 | 5.5 | 5.5 | · | 5.4 | |
| Quick Ratio | 2.6 | 2.8 | · | 3.2 | 3.6 | 3.9 | · | 4.3 | 4.4 | 4.4 | · | 4.3 | 4.5 | 4.5 | · | 4.4 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 46.7 | · | 62.4 | 53.8 | 52.6 | · | 80.0 |
दक्षता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.5 |
मूल्यांकन (TTM) 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $15.33B | $14.06B | · | $14.18B | $13.97B | $13.44B | · | $13.78B | $13.21B | $12.83B | · | $12.62B | $12.11B | $11.92B | · | $12.21B | |
| Net Income TTM | $4.88B | $4.39B | · | $5.00B | $4.97B | $4.30B | · | $4.50B | $4.13B | $3.52B | · | $4.11B | $3.95B | $3.96B | · | $4.77B | |
| Market Cap | $86.05B | $106.55B | · | $76.58B | $71.50B | $86.32B | · | $142.23B | $141.68B | $129.17B | · | $108.71B | $94.56B | $107.97B | · | $88.86B | |
| Enterprise Value | $80.04B | $99.78B | · | $70.12B | $66.02B | $79.95B | · | $134.42B | $133.85B | $120.63B | · | $100.78B | $87.61B | $100.99B | · | $83.82B | |
| P/E | 13.7 | 19.1 | · | 12.4 | 11.9 | 16.9 | · | 26.9 | 29.1 | 31.2 | · | 22.7 | 20.6 | 23.5 | · | 16.4 | |
| P/S | 5.6 | 7.6 | · | 5.4 | 5.1 | 6.4 | · | 10.3 | 10.7 | 10.1 | · | 8.6 | 7.8 | 9.1 | · | 7.3 | |
| P/B | 2.7 | 3.4 | · | 2.5 | 2.4 | 2.9 | · | 4.9 | 5.0 | 4.8 | · | 4.4 | 3.9 | 4.6 | · | 4.1 | |
| P / Tangible Book | 2.8 | 3.5 | · | 2.6 | 2.5 | 3.1 | · | 5.0 | 5.2 | 5.0 | · | 4.6 | 4.1 | 4.8 | · | 4.3 | |
| P / Cash Flow | · | 98.8 | · | · | · | 82.6 | · | · | · | 85.4 | · | · | · | 78.9 | · | · | |
| P / FCF | · | 125.6 | · | · | · | 105.8 | · | · | · | 93.7 | · | · | · | 90.8 | · | · | |
| EV / EBITDA | 61.9 | 130.2 | · | 68.3 | 61.2 | 111.3 | · | 114.0 | 125.1 | 139.4 | · | 90.7 | 86.2 | 96.5 | · | 68.5 | |
| EV / FCF | · | 117.6 | · | · | · | 98.0 | · | · | · | 87.5 | · | · | · | 84.9 | · | · | |
| EV / Revenue | 5.2 | 7.1 | · | 4.9 | 4.7 | 5.9 | · | 9.8 | 10.1 | 9.4 | · | 8.0 | 7.2 | 8.5 | · | 6.9 | |
| Earnings Yield | 7.3% | 5.2% | · | 8.1% | 8.4% | 5.9% | · | 3.7% | 3.4% | 3.2% | · | 4.4% | 4.8% | 4.2% | · | 6.1% | |
| Payout Ratio | · | 13.5% | · | · | · | 11.6% | · | · | · | · | · | · | · | · | · | · |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| परिचालन मार्जिन % | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% |
| शुद्ध आय | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| तनुकरणित EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| ऋण / इक्विटी | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| वर्तमान अनुपात | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 |
| त्वरित अनुपात | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
- FDG की होल्डिंग्स 20% गेन क्षमता का संकेत देती हैं
- iShares MSCI USA Min Vol Factor ETF को बड़े बहिर्वाह का अनुभव
- रेजेनरॉन फार्मास्युटिकल्स (REGN) ने टेलिक्स फार्मास्युटिकल्स लिमिटेड के साथ सहयोग की घोषणा की
- कमाई पूर्वावलोकन: Regeneron Pharmaceuticals की रिपोर्ट से क्या उम्मीद करें
- रीजेनरॉन फार्मा, रेडियोफार्मास्युटिकल थेरेपीज को संयुक्त रूप से विकसित करने के लिए टेलिक्स फार्मा के साथ साझेदारी
- जिम क्रैमर रेजेनरॉन (REGN) पर: 'मुझे लगता है कि स्टॉक यहां ब्रेकआउट कर रहा है'
- टेलिक्स और रीजेनरॉन अगली पीढ़ी के रेडियोफार्मास्युटिकल उपचारों को आगे बढ़ाने के लिए साझेदारी कर रहे हैं
- Formycon ने Regeneron, Bayer सेटलमेंट के बाद FYB203 के लिए यूरोप लॉन्च टाइमिंग हासिल की
- क्या रीजेनरॉन फार्मास्यूटिकल्स, इंक. (REGN) खरीदने के लिए एक अच्छा स्टॉक है?
ट्रेडिंग सिग्नल प्रवेश मूल्य और जोखिम/इनाम अनुपात के साथ हालिया खरीद/बिक्री संकेत
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 1481 फाइलर्स · $34.8B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 124 (-35 पिछली तिमाही की तुलना में) | 162 (+63 पिछली तिमाही की तुलना में) | 481 (-68 पिछली तिमाही की तुलना में) | 526 (+45 पिछली तिमाही की तुलना में) | +9.2M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $4133919926 | 6629759 | 11.89% | शेयर |
| Dodge & Cox | $3037348765 | 4871137 | 8.73% | शेयर |
| STATE STREET CORP | $3014621356 | 4834688 | 8.67% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1979934668 | 3175313 | 5.69% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $1427303015 | 2297074 | 4.10% | शेयर |
| LOOMIS SAYLES & CO L P | $1014501372 | 1627003 | 2.92% | शेयर |
| PeakShares LLC | $975217000 | 1564 | 2.80% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $763126911 | 1223862 | 2.19% | शेयर |
| NORGES BANK | $731292700 | 1172808 | 2.10% | शेयर |
| Capital World Investors | $508138359 | 814925 | 1.46% | शेयर |
| TWO SIGMA ADVISERS, LP | $466626290 | 604540 | 1.34% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $432674406 | 693900 | 1.24% | पुट ऑप्शन |
| TWO SIGMA INVESTMENTS, LP | $409119559 | 656124 | 1.18% | शेयर |
| GOLDMAN SACHS GROUP INC | $392576914 | 629594 | 1.13% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $351496357 | 563711 | 1.01% | शेयर |
| FIRST TRUST ADVISORS LP | $341158711 | 547132 | 0.98% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $299532285 | 480373 | 0.86% | शेयर |
| Robeco Institutional Asset Management B.V. | $287203770 | 460602 | 0.83% | शेयर |
| NEUBERGER BERMAN GROUP LLC | $259935179 | 416870 | 0.75% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $249320598 | 399847 | 0.72% | शेयर |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $245478345 | 393685 | 0.71% | शेयर |
| National Pension Service | $236829845 | 379815 | 0.68% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $236259306 | 378900 | 0.68% | कॉल ऑप्शन |
| ALLIANCEBERNSTEIN L.P. | $225872032 | 292338 | 0.65% | शेयर |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $220714454 | 353970 | 0.63% | शेयर |
| BlackRock, Inc. | $207677479 | 333062 | 0.60% | शेयर |
| JANE STREET GROUP, LLC | $198659844 | 318600 | 0.57% | कॉल ऑप्शन |
| Swiss National Bank | $182709691 | 293020 | 0.53% | शेयर |
| Sumitomo Mitsui Trust Group, Inc. | $175962364 | 282199 | 0.51% | शेयर |
| BANK OF AMERICA CORP /DE/ | $171791505 | 275510 | 0.49% | शेयर |
| CITADEL ADVISORS LLC | $169166402 | 271300 | 0.49% | कॉल ऑप्शन |
| FIL Ltd | $165543635 | 265490 | 0.48% | शेयर |
| CITADEL ADVISORS LLC | $164988684 | 264600 | 0.47% | पुट ऑप्शन |
| FMR LLC | $162474852 | 260568 | 0.47% | शेयर |
| TD Asset Management Inc | $161694522 | 259317 | 0.46% | शेयर |
| Mitsubishi UFJ Asset Management Co., Ltd. | $160530373 | 257450 | 0.46% | शेयर |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $159939881 | 256503 | 0.46% | शेयर |
| Nuveen, LLC | $158965911 | 254941 | 0.46% | शेयर |
| Caisse de depot et placement du Quebec | $156264112 | 250608 | 0.45% | शेयर |
| Assenagon Asset Management S.A. | $152721782 | 244927 | 0.44% | शेयर |
| Vanguard Global Advisers, LLC | $141371483 | 226724 | 0.41% | शेयर |
| California Public Employees Retirement System | $139840692 | 224269 | 0.40% | शेयर |
| Qube Research & Technologies Ltd | $138180829 | 221607 | 0.40% | शेयर |
| Legal & General Group Plc | $134385341 | 215520 | 0.39% | शेयर |
| CANADA PENSION PLAN INVESTMENT BOARD | $130887905 | 209911 | 0.38% | शेयर |
| Squarepoint Ops LLC | $123814467 | 198567 | 0.36% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $123317506 | 197770 | 0.35% | शेयर |
| Candriam S.C.A. | $121893176 | 195674 | 0.35% | शेयर |
| MCDONALD CAPITAL INVESTORS INC/CA | $120366915 | 193038 | 0.35% | शेयर |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $119141861 | 154201 | 0.34% | शेयर |
| Swedbank AB | $118377821 | 189848 | 0.34% | शेयर |
| Carmignac Gestion | $113826706 | 182507 | 0.33% | शेयर |
| BANK OF NOVA SCOTIA | $113300959 | 181706 | 0.33% | शेयर |
| JANE STREET GROUP, LLC | $112548970 | 180500 | 0.32% | पुट ऑप्शन |
| BARCLAYS PLC | $111306254 | 178507 | 0.32% | शेयर |
| PANAGORA ASSET MANAGEMENT INC | $109300950 | 175291 | 0.31% | शेयर |
| GOLDMAN SACHS GROUP INC | $106687694 | 171100 | 0.31% | कॉल ऑप्शन |
| MILLENNIUM MANAGEMENT LLC | $102958925 | 165120 | 0.30% | शेयर |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $102237489 | 163963 | 0.29% | शेयर |
| Bronte Capital Management Pty Ltd. | $101398828 | 162618 | 0.29% | शेयर |
| NORDEA INVESTMENT MANAGEMENT AB | $100247789 | 160258 | 0.29% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $99201835 | 159095 | 0.29% | शेयर |
| RHUMBLINE ADVISERS | $98390781 | 157794 | 0.28% | शेयर |
| Pictet Asset Management Holding SA | $96459212 | 153500 | 0.28% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $92422346 | 148222 | 0.27% | शेयर |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $92259602 | 147961 | 0.27% | शेयर |
| AMERIPRISE FINANCIAL INC | $90305429 | 144827 | 0.26% | शेयर |
| MACKENZIE FINANCIAL CORP | $84666132 | 135783 | 0.24% | शेयर |
| PRUDENTIAL FINANCIAL INC | $81380076 | 130513 | 0.23% | शेयर |
| Retirement Systems of Alabama | $79731436 | 127869 | 0.23% | शेयर |
| MARSHALL WACE, LLP | $79189580 | 127000 | 0.23% | पुट ऑप्शन |
| Sound Shore Management Inc /CT/ | $79185839 | 126994 | 0.23% | शेयर |
| VICTORY CAPITAL MANAGEMENT INC | $78779916 | 126343 | 0.23% | शेयर |
| ProShare Advisors LLC | $74350910 | 119240 | 0.21% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $69443026 | 111369 | 0.20% | शेयर |
| ENVESTNET ASSET MANAGEMENT INC | $68488193 | 109838 | 0.20% | शेयर |
| Gotham Asset Management, LLC | $65574584 | 105165 | 0.19% | शेयर |
| Harvest Portfolios Group Inc. | $65232261 | 104616 | 0.19% | शेयर |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $62737149 | 100286 | 0.18% | शेयर |
| Mariner, LLC | $61632002 | 98826 | 0.18% | शेयर |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $61471693 | 98585 | 0.18% | शेयर |
| PARNASSUS INVESTMENTS, LLC | $59471998 | 95378 | 0.17% | शेयर |
| Davern Capital Partners, LP | $57764746 | 92640 | 0.17% | शेयर |
| AVIVA PLC | $57045180 | 91486 | 0.16% | शेयर |
| PFA Pension, Forsikringsaktieselskab | $56561245 | 90710 | 0.16% | शेयर |
| ARMISTICE CAPITAL, LLC | $55999504 | 89809 | 0.16% | शेयर |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $54996852 | 88201 | 0.16% | शेयर |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $52429737 | 84084 | 0.15% | शेयर |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $52158497 | 83649 | 0.15% | शेयर |
| ROYAL BANK OF CANADA | $51450000 | 82513 | 0.15% | शेयर |
| CWM, LLC | $51303491 | 66400 | 0.15% | शेयर |
| PINNACLE ASSOCIATES LTD | $50660926 | 81247 | 0.15% | शेयर |
| GROUPAMA ASSET MANAGMENT | $49128285 | 77940 | 0.14% | शेयर |
| NEOS Investment Management LLC | $48213359 | 77322 | 0.14% | शेयर |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | $46765500 | 75000 | 0.13% | शेयर |
| Korea Investment CORP | $46737441 | 74955 | 0.13% | शेयर |
| Grantham, Mayo, Van Otterloo & Co. LLC | $46266668 | 74200 | 0.13% | शेयर |
| WOLVERINE TRADING, LLC | $45925425 | 81900 | 0.13% | कॉल ऑप्शन |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $45875500 | 59375 | 0.13% | शेयर |
| Woodline Partners LP | $45265886 | 72595 | 0.13% | शेयर |
कंपनी के अंदरूनी सूत्र 39 इनसाइडर्स · 3 अधिकारी · 7 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | 31 दिसमबर 2025 M | 214523 | 0 | 0 | $0 |
| Christopher R. Fenimore | SVP Controller | 20 अगस्त 2021 F | 19020 | 0 | 0 | $0 |
| Van Plew Daniel P | EVP & General Mgr Industrial O | 20 अगस्त 2020 M | 47110 | 0 | 0 | $0 |
| Arthur F Ryan | निदेशक | 2 जुलाई 2026 S | 17303 | 0 | 48 | $-434683 |
| Anthony N Coles | निदेशक | 2 जनवरी 2026 A | 1714 | 0 | 0 | $0 |
| Christine A Poon | निदेशक | 2 जनवरी 2026 A | 5219 | 0 | 6 | $-4252745 |
| Michael S Brown | निदेशक | 2 जनवरी 2026 A | 1703 | 0 | 0 | $0 |
| David P Schenkein | निदेशक | 8 सितमबर 2023 A | 240 | 0 | 0 | $0 |
| Craig B. Thompson | निदेशक | 3 अक्टूबर 2022 A | 279 | 0 | 0 | $0 |
| REGENERON PHARMACEUTICALS, INC. | 10% मालिक | 17 फ़रवरी 2021 C | 2097314 | 0 | 0 | $0 |
| Sanofi | 10% मालिक | 9 जून 2020 S | 279766 | 0 | 0 | $0 |
| Pharma Ag Novartis | 10% मालिक | 8 नवमबर 2005 S | — | 0 | 0 | $0 |
| Kathryn Guarini | — | 10 अगस्त 2026 M | 603 | 0 | 1 | $-320000 |
| Huda Y Zoghbi | — | 10 अगस्त 2026 M | 1703 | 0 | 1 | $-640000 |
| Joseph L Goldstein | — | 2 जनवरी 2026 A | 6703 | 0 | 0 | $0 |
| George L Sing | — | 2 जनवरी 2026 A | 31007 | 0 | 0 | $0 |
| George Yancopoulos | — | 31 दिसमबर 2025 M | 310460 | 0 | 0 | $0 |
| Joseph J Larosa | — | 5 दिसमबर 2025 A | 29517 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | — | 9 दिसमबर 2021 M | 2078 | 0 | 0 | $0 |
| Marion Mccourt | — | 7 जून 2021 M | 17038 | 0 | 0 | $0 |
| Andrew J Murphy | — | 9 दिसमबर 2020 A | 57350 | 0 | 0 | $0 |
| Robert E Landry | — | 9 दिसमबर 2020 A | 25903 | 0 | 0 | $0 |
| Neil Stahl | — | 9 दिसमबर 2020 A | 24715 | 0 | 0 | $0 |
| Bonnie L Bassler | — | 19 जून 2020 M | 643 | 0 | 0 | $0 |
| VAGELOS P ROY | — | 16 दिसमबर 2019 I | 2200 | 0 | 0 | $0 |
| Charles A Baker | — | 2 जनवरी 2018 A | 9000 | 0 | 0 | $0 |
| Robert J Terifay | — | 12 दिसमबर 2017 A | 23293 | 0 | 0 | $0 |
| Michael S Aberman | — | 16 दिसमबर 2016 A | 16498 | 0 | 0 | $0 |
| Peter Powchik | — | 16 दिसमबर 2016 A | 2459 | 0 | 0 | $0 |
| Douglas S Mccorkle | — | 29 दिसमबर 2015 M | 6866 | 0 | 0 | $0 |
| Alfred G Gilman | — | 6 अगस्त 2015 M | 8912 | 0 | 0 | $0 |
| Robert Alexander Ingram | — | 22 मई 2015 M | 1500 | 0 | 0 | $0 |
| Murray A Goldberg | — | 16 दिसमबर 2014 A | 64436 | 0 | 0 | $0 |
| Eric M Shooter | — | 12 फ़रवरी 2014 M | 0 | 0 | 0 | $0 |
| William Roberts | — | 18 सितमबर 2013 M | 13447 | 0 | 0 | $0 |
| Stuart Kolinski | — | 3 जून 2010 M | 16329 | 0 | 0 | $0 |
| Peter Dworkin | — | 18 दिसमबर 2009 A | — | 0 | 0 | $0 |
| Randall Rupp | — | 13 अप्रैल 2007 M | 3983 | 0 | 0 | $0 |
| Hans Peter Guler | — | 8 अक्टूबर 2004 M | 10530 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 2 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC., SYMPHONY ACQUISITION SUB, INC. ×2 फाइलिंग | 27 सितमबर 2023 | — | प्रारंभिक फाइलिंग | — | SEC |
| Sanofi ×17 फाइलिंग | 17 जून 2020 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 237 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| TBXU · Direxion Shares ETF Trust | 8.55% | 357 NS | 30 अप्रैल 2026 | N-PORT |
| IBB · iShares Trust | 6.00% | 740981 SH | 8 अगस्त 2026 | दैनिक |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 5.51% | 5609 SH | 8 अगस्त 2026 | दैनिक |
| PBE · Invesco Exchange-Traded Fund Trust | 5.42% | 25033 SH | 8 अगस्त 2026 | दैनिक |
| IDNA · iShares Trust | 4.25% | 10887 SH | 8 अगस्त 2026 | दैनिक |
| BIB · ProShares Trust | 3.21% | 3840 NS | 31 मई 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 3.14% | 20280 SH | 8 अगस्त 2026 | दैनिक |
| QQQA · ProShares Trust | 2.93% | 2168 NS | 31 मई 2026 | N-PORT |
| AGNG · Global X Funds | 2.48% | 3299 NS | 31 मई 2026 | N-PORT |
| SDG · iShares Trust | 2.28% | 5119 SH | 8 अगस्त 2026 | दैनिक |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 2.19% | 344 NS | 30 अप्रैल 2026 | N-PORT |
| QQQG · Pacer Funds Trust | 2.18% | 348 NS | 30 अप्रैल 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.98% | 24491 NS | 30 अप्रैल 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.98% | 19712 SH | 8 अगस्त 2026 | दैनिक |
| SGLC · RBB Fund, Inc. | 1.87% | 5922 NS | 31 मई 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.78% | 1346 NS | 30 अप्रैल 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1.67% | 1408 NS | 31 मई 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.64% | 37398 SH | 8 अगस्त 2026 | दैनिक |
| TECB · iShares Trust | 1.60% | 9957 SH | 8 अगस्त 2026 | दैनिक |
| BBP · ETFis Series Trust I | 1.52% | 1276 NS | 30 अप्रैल 2026 | N-PORT |
| QNXT · iShares Trust | 1.48% | 539 SH | 8 अगस्त 2026 | दैनिक |
| RILA · Spinnaker ETF Series | 1.44% | 854 NS | 30 अप्रैल 2026 | N-PORT |
| COWG · Pacer Funds Trust | 1.40% | 43095 NS | 30 अप्रैल 2026 | N-PORT |
| FLAG · Global X Funds | 1.29% | 30 NS | 30 अप्रैल 2026 | N-PORT |
| IYH · iShares Trust | 1.27% | 60521 SH | 8 अगस्त 2026 | दैनिक |
| NUGO · Nushares ETF Trust | 1.27% | 50872 NS | 30 अप्रैल 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1.19% | 1758 NS | 31 मई 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.19% | 4569 NS | 30 अप्रैल 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1.18% | 47616 NS | 30 अप्रैल 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1.17% | 299615 NS | 30 अप्रैल 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.16% | 770 NS | 30 अप्रैल 2026 | N-PORT |
| IMCV · iShares Trust | 1.08% | 16108 SH | 8 अगस्त 2026 | दैनिक |
| CURE · Direxion Shares ETF Trust | 1.03% | 2010 NS | 30 अप्रैल 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.99% | 444 NS | 30 अप्रैल 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0.99% | 540 NS | 30 अप्रैल 2026 | N-PORT |
| IXJ · iShares Trust | 0.98% | 52534 SH | 8 अगस्त 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | 0.95% | 312338 SH | 8 अगस्त 2026 | दैनिक |
| FLCV · Federated Hermes ETF Trust | 0.90% | 1412 NS | 31 मई 2026 | N-PORT |
| RXL · ProShares Trust | 0.90% | 1051 NS | 31 मई 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0.87% | 14942 NS | 30 अप्रैल 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.85% | 6267 NS | 30 अप्रैल 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0.79% | 87 NS | 31 मई 2026 | N-PORT |
| TAX · EA Series Trust | 0.78% | 324 NS | 29 मई 2026 | N-PORT |
| QIDX · Spinnaker ETF Series | 0.77% | 419 NS | 30 अप्रैल 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.75% | 2512 NS | 30 अप्रैल 2026 | N-PORT |
| CANC · Tema ETF Trust | 0.75% | 2138 NS | 31 मई 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.73% | 8277 SH | 8 अगस्त 2026 | दैनिक |
| FLRG · FIDELITY COVINGTON TRUST | 0.72% | 2871 NS | 30 अप्रैल 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0.69% | 448 NS | 30 अप्रैल 2026 | N-PORT |
| FLCC · Federated Hermes ETF Trust | 0.69% | 1360 NS | 31 मई 2026 | N-PORT |